Stay updated on Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial page.

Latest updates to the Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial page
- Check6 days agoChange DetectedThe NIH terminology-transition announcement banner was removed from the page. The underlying study page still displays a 403 Forbidden error.SummaryDifference1%

- Check13 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0, while the study page remains unavailable with a 403 Forbidden message.SummaryDifference0.2%

- Check27 days agoChange DetectedA sitewide notice about NIH’s transition from using “Artificial Intelligence” to “Super Intelligence” appears above the page, and the footer revision changes from v3.7.1 to v3.7.2.SummaryDifference1%

- Check40 days agoChange DetectedThe site’s footer revision number changes from v3.7.0 to v3.7.1 on the 403 error page.SummaryDifference0.2%

- Check47 days agoChange DetectedThe page previously displayed a 403 Forbidden error, and now shows the full study record for the trial, including the overview, design, primary and secondary outcomes, eligibility criteria, and contacts/locations.SummaryDifference100%

- Check54 days agoChange DetectedThe page now displays a 403 Forbidden error, replacing the study content with a simple error screen and a Home link. Users cannot view the study details or related information on this page.SummaryDifference17%

Stay in the know with updates to Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Chemotherapy in Relapsed SCLC - Clinical Trial page.